285 related articles for article (PubMed ID: 29596219)
21. A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age.
Kim J; Nakwa FL; Araujo Motta F; Liu H; Dorr MB; Anderson LJ; Kartsonis N
J Antimicrob Chemother; 2020 Jan; 75(1):215-220. PubMed ID: 31586424
[TBL] [Abstract][Full Text] [Related]
22. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
Glöckner A
Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
[TBL] [Abstract][Full Text] [Related]
23. Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: A systematic review and meta-analysis.
Yamashita C; Takesue Y; Matsumoto K; Ikegame K; Enoki Y; Uchino M; Miyazaki T; Izumikawa K; Takada T; Okinaka K; Ueda T; Miyazaki Y; Mayumi T
J Infect Chemother; 2020 Jun; 26(6):596-603. PubMed ID: 32171659
[TBL] [Abstract][Full Text] [Related]
24. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
[TBL] [Abstract][Full Text] [Related]
25. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
26. Caspofungin versus liposomal amphotericin B for treatment of invasive fungal infections or febrile neutropenia.
Zhang J; Gong Y; Wang K; Kong J; Chen Y
Chin Med J (Engl); 2014; 127(4):753-7. PubMed ID: 24534235
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of echinocandin monotherapy and combination therapy for immunocompromised patients with systemic candidiasis: A systematic review and meta-analysis.
Tang BHE; Bay JW; Yeong FM; Samuel M
J Mycol Med; 2023 May; 33(2):101362. PubMed ID: 36867970
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
29. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
30. [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].
Montejo M; Quindós G
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():15-22. PubMed ID: 21420572
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.
Kaskel P; Tuschy S; Wagner A; Bannert C; Cornely OA; Glasmacher A; Lipp HP; Ullmann AJ
Ann Hematol; 2008 Apr; 87(4):311-9. PubMed ID: 17929018
[TBL] [Abstract][Full Text] [Related]
33. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
35. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
[TBL] [Abstract][Full Text] [Related]
36. Echinocandins: the newest class of antifungals.
Sucher AJ; Chahine EB; Balcer HE
Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
León-Gil C; Ubeda-Iglesias A; Loza-Vázquez A; de la Torre MV; Raurich-Puigdevall JM; Alvarez-Sánchez B; Ortiz-Leyva C; Domínguez-Roldán JM; Socías-Crespi L; Garnacho-Montero J;
Rev Esp Quimioter; 2012 Dec; 25(4):274-82. PubMed ID: 23303260
[TBL] [Abstract][Full Text] [Related]
38. Caspofungin therapy in immunocompromised children and neonates.
Somer A; Törün SH; Salman N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
[TBL] [Abstract][Full Text] [Related]
39. [Micafungin for the treatment of neonatal invasive candidiasis].
Infante-López ME; Rojo-Conejo P
Rev Iberoam Micol; 2009 Mar; 26(1):56-61. PubMed ID: 19463278
[TBL] [Abstract][Full Text] [Related]
40. Invasive fungal infections in newborns and current management strategies.
Hundalani S; Pammi M
Expert Rev Anti Infect Ther; 2013 Jul; 11(7):709-21. PubMed ID: 23829639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
